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Abstract
Background: The clearance of hepatitis B virus (HBV) is a complex process which may be influenced by many factors
including polymorphisms in the tumor necrosis factor ,alpha. (TNF-,alpha.) gene promoter. However, previous reports
regarding the relationship between polymorphisms in the TNF-,alpha. promoter and HBV clearance have been
inconsistent. Therefore, we performed a meta-analysis on a large population to address this inconsistency.
Methods: A meta-analysis was performed to examine the association between TNF-,alpha. promoter polymorphisms
(-1031T/C, -863C/A, -857C/T, -308G/A and-238G/A) and chronic hepatitis B infection. Odds ratio (OR) and its 95 % confidence
interval (CI) were used.
Results: Twelve studies were chosen in our meta-analysis, involving 2,754 chronic HBV infection cases and 1,630 HBV
clearance cases. The data showed that TNF-,alpha.-863 CC genotype was significantly associated with HBV clearance
(-863 CC vs. AA: OR, 0.64; 95% CI, [0.42, 0.97]; p=0.04) while patients carrying -308 GG genotype had a significantly
increased risk of HBV persistence compared with those with GA or AA genotype (GG vs. GA+AA: OR, 1.35; 95% CI, [1.08,
1.70]; p=0.01). For the other polymorphisms, no association with HBV infection outcome was found.
Conclusions: The data showed that polymorphisms -863 A and -308 G in the TNF-,alpha. gene promoter region might be
risk factors for HBV persistence. Furthermore, ethnicity might play an important role in HBV infection outcome, leading to
conflicting results. More studies on individuals from various ethnic groups will be necessary to determine the role of TNF-
,alpha. promoter polymorphisms in the outcome of HBV infection.
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Introduction
Approximately 5–10% of patients infected with hepatitis B virus
(HBV) as adults are unable to clear the virus, ultimately developing
chronic HBV infections[1]. The persistence of the virus is thought
to be largely caused by a deficiency of the immune response to
HBV[1]. The virus itself, environment factors, ethnic differences,
and genetic susceptibility have also been reported to have some
influence on the progression of this liver disease [2]. Recently,
cytokine genetic polymorphisms have been found to be related
factors that affect the progression of HBV infection [1].
Tumor necrosis factor ,alpha. (TNF-,alpha.)i sp r o d u c e db y
macrophages, monocytes, neutrophils, T-cells and NK-cells after
stimulation. In turn, TNF-,alpha. can stimulate cytokine secretion,
increase the expression of adhesion molecules as well as activate
neutrophils. Hence, it fulfills the role as a principal mediator of cellular
immune response and inflammation, and may play an importance
role in non-cytolytic and cytolytic clearance of HBV [3,4,5].
The TNF-,alpha. gene is located in the class III region of the
major histocompatibility complex (MHC) on chromosome 6. The
amount of cytokine production seems to be affected by the
polymorphisms in the regulatory region. Therefore, there might be
relationships between these single nucleotide polymorphisms
(SNPs) and cytokine-mediated inflammation, which may affect
the outcome of the disease.
There have been a number of studies on the association
between chronic HBV infection (CHB), HBV clearance (HC), and
TNF-,alpha. promoter polymorphisms -1031T/C, -863 C/A,
-857C/T, -308G/A, and-238G/A. However, the results have
been inconsistent. For instance, some studies indicated that
patients carrying TNF-,alpha. genotypes (AA for -863, CC for
-857, AA for -308, and AA for -283) have a higher risk of
susceptibility to persistence of HBV [6,7,8,9] while other studies
did not[10,11,12].
A single study may fail to completely demonstrate this
complicated genetic relationship because of a small sample size,
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19606which has low statistical power. Larger studies could overcome
these disadvantages. Therefore, we performed a meta-analysis in
an attempt to resolve this issue.
Methods
Search strategy
We searched the PubMed, EMBASE, ISI Web of Science,
Google Scholar, Chinese National Knowledge Infrastructure
Database and China Biological Medicine Database to collect all
papers associated TNF-,alpha. polymorphism and HBV (last
search update: 31
st July 2010). The following key words were used:
‘‘hepatitis B’’, ‘‘HBV’’, ‘‘Tumor necrosis factor ,alpha.’’, ‘‘TNF-
,alpha.’’, ‘‘polymorphism’’ and ‘‘SNP’’. We also combined these
key words to maximize the sample size in our analysis. TNF-
,alpha. promoter polymorphisms -1031T/C, -863 C/A, -857C/
T, -308G/A and-238G/A were investigated. The electronic
searching was supplemented by checking reference lists from
identified articles and reviews for additional original reports The
language of the reviewed articles was limited to Chinese and
English. Data were extracted by two authors independently and a
consensus was achieved for all data. We excluded studies that were
not full-length publications, and those that included no more than
10 participants. When study recruitment overlapped by more than
30% in two or more articles by the same author(s), the one with
the largest population of participants or the most recent one was
selected. We used Chi-square test to evaluate whether the
observed frequencies of genotypes conformed to Hardy-Weinberg
Equilibrium (HWE). CHB was defined as a condition in which
serum HBsAg was positive for at least 6 months. HBV clearance
(HC) was defined as a condition in which HBsAg was negative, but
both HBV core antibody (anti-HBc) and HBV surface antibody
(anti-HBs) were positive. None of the patients included in our
study had any other type of liver disease such as hepatitis C or
alcoholic liver disease.
Data extraction
The following information was extracted by two authors
independently, and a consensus was achieved: first author’s name,
year of publication, country, mean age of the study subjects, gender
component, genotyping method, cases of CHB and HC with
various genotypes, polymorphisms of TNF-,alpha. promoter.
Statistical analysis
Odds ratios (ORs) with their confidence intervals (CIs) were
calculated for each study. Heterogeneity was tested by chi-square-
based Q test and I
2=100%6(Q-df)/Q [13,14]. The fixed effects
model (Mantel–Haenszel method) [15] was used for calculating
the pooled OR when the P value .0.05 for the Q test which
indicated absence of heterogeneity among the studies. Otherwise,
we used a random-effects model (DerSimonian-Laird method).
Publication bias tests were performed by using the funnel plot, in
which the standard error of log (OR) of each study was plotted
against its log (OR). Funnel plot asymmetry was evaluated by
Egger’s linear regression test. A P value ,0.10 was considered to
indicate statistically significant publication bias.
Results
Extraction process and characteristics of the studies
One hundred and six studies were identified after searching the
databases. Seventy-six studies that not focused on chronic
HBV(e.g. Severe Hepatitis B infection, Hepatitis C or D infection,
liver fibrosis, hepatocellular carcinoma, intrauterine infection, etc.)
were excluded after title review. Twelve studies were excluded
after abstract review, three of them were not focusing on chronic
HBV and eight lacked HC cases and one was a review article.
After full text review, six studies were excluded, two of them not
focused on chronic HBV and two were lacking HC cases and the
other two were previously written by the same authors(Cheong,
J.Y. et al [16] and Li, H. Q. et al [17]) of the rest studies, we selected
the latest ones[10,18]. The extraction process was showed in Fig 1.
Finally a total of 12 relevant studies were selected [6,8,9,10,
11,12,18,19,20,21,22,23] involving 2754 chronic HBV infection
cases and 1630 HBV clearance cases. All studies included that the
distribution of genotypes in the controls or recovered was
consistent with Hardy-Weinberg equilibrium, except for two
studies for -857C/T(Chen,D.Q et al[6])and -308G/A(Xing,P.X.
et al [24]) .The included studies had been conducted on Chinese,
Korean, Thai, Italian, Iranian, Brazilian and German partici-
pants. A summary of characteristics of these 12 included studies
was showed in Table 1.
Meta-analysis
Table 2 lists the results of the meta-analysis and heterogeneity
test. Because the study by Kummee et al [20] contained a large
number of individuals with HCC, subjects with or without HCC
were included in our studies.
For TNF-,alpha.-1031T/C and, -857C/T, we found no
association between the polymorphisms and HBV clearance. For
TNF-,alpha.-863, overall, we found that compared to -863
AA,TNF-,alpha.-863 CC genotype was associated with chronic
HBV clearance (-863 CC vs. AA:OR, 0.64; 95% CI, [0.42, 0.97];
p=0.04) (Fig 2). When we excluded the subjects with HCC, the
signification seemed to be weaken(OR, 0.66; 95% CI, [0.43, 1.00];
p=0.05),implying that -863 CC might play a relatively different
role in HCC patients. In a subgroup analysis of TNF-,alpha.-863
CC vs. AA by ethnicity, the pooled OR was significant in Asians
(OR, 0.64; 95% CI, [0.11, 0.99]; p=0.04). In addition, the result
of AA vs. CA+CC model showed that -863 AA maybe a risk factor
for HBV persistence (overall: OR, 1.60; 95% CI, [1.06, 2.41];
p=0.02;Asian: OR, 1.60; 95% CI, [1.05, 2.45]; p=0.02) which
implied the counteractive function between -863 CC and -863 AA
in virus clearance. A European subgroup analysis was not
conducted because only one study [8] was available.
When we performed analysis on TNF-,alpha.-308 G/A we
found two models had statistic significance(G allele vs. A allele: OR,
1.30; 95% CI, [0.104, 1.63]; p=0.02 . GG vs. GA+AA: OR, 1.35;
95% CI, [1.08, 1.70]; p=0.01) (Fig. 3) indicating that -308 G might
be an unfavorable factor for the elimination of HBV. In subgroup
analysis,theresultofAsiangroupwassimilar(Gallelevs. Aallele:OR,
1.41; 95% CI, [1.08, 1.83]; p=0.01; GGvs. GA+AA: OR, 1.47; 95%
CI, [1.13, 1.91]; p=0.004) while the European group lacked such an
association. We also performed an analysis for East Asian individuals
by removing a study conducting on Iraqi(Somi, M. H [12]) from
Asian group , the result still stable(G allele vs. A allele:OR, 1.49; 95%
CI, [1.12, 1.98]; p=0.006; GG vs. GA+A A :O R ,1 . 5 6 ;9 5 %C I ,
[1.17, 2.08]; p=0.002). When we excluded the subjects with HCC,
the results remained similar(data not show).
Interestingly, significantly increased risks were observed in the
European population (-238 GG vs. GA+AA: OR, 0.45; 95% CI,
[0.22, 0.93]; p=0.03), but not in the Asian population or overall
analysis.
Tests of heterogeneity
We found heterogeneities in three studies: (-863 CC vs. CA+AA,
overall: x
2=17.06, p=00.004, I
2=71%; Asian: x
2=17.06,
p=0.002, I
2=77%; -857 CC vs. CT +TT , x
2=9.47, p=0.009,
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2=79%) (Table 2). A random-effects model was employed in
these studies.
Publication bias
Begg’s funnel plot and Egger’s test were performed to access the
publication bias of the studies. No evidence of publication bias
showed in -308 G allele vs. A allele or -308 GG vs. AA model
(funnel plot data not show, Egger’s test p=0.470 and 0.556,re-
spectively). However, funnel plot showed some asymmetry in -863
CC vs. AA and -863 AA vs. CA+CC models(Fig 4) and Egger’s
proved the existence of publication in these two models(p=0.041
and 0.038, respectively). We excluded one study from the meta-
analysis to see whether the publication bias still presented. The
results showed that after the exclusion of study Chen, D. Q. et al
[6], the publication bias was eliminated(funnel plot showed in
Fig 4, Egger’s test -863 CC vs. AA:p=0.785; -863 AA vs.
CA+CC:p=0.541),and the conclusion still stable(-863 CC vs. AA:
OR, 0.42; 95% CI, [0.23, 0.77]; p=0.005; -863 AA vs. CA+CC:
OR, 2.44; 95% CI, [1.34, 4.45]; p=0.003).
Discussion
The mechanism of effective clearance of HBV from the human
body is likely related to both environmental and host genetic
factors. Several studies have reported that TNF-,alpha. plays an
important role in HBV clearance. In an in vitro study, TNF-
,alpha. was reported to be able to accelerate HBV mRNA
destruction, and inhibit the replication of HBV[25]. An in vivo
study also found that TNF limited chronic infection by
destabilizing HBV nucleocapsids and reducing the cccDNA[26].
Furthermore, a clinical study showed that elevation of TNF-
,alpha. levels in IFN-,alpha.treated patients led to HBV
elimination[27].
In the current study, we performed a meta-analysis to examine
the association between the SNPs in the promoter region of TNF-
,alpha. and the outcome of HBV infection. According to our
findings, the presence of G at the position -308 of TNF-,alpha.
promoter gene polymorphisms increased the risk of HBV
persistent infection significantly while -308 A may have a positive
effect in virus clearance. Similar conclusion was drew by Zheng,
M. H. et al [28] who also performed a meta-analysis focus on
healthy individual(including spontaneously recovered case)and
Chronic hepatitis B patient, they found that -308 A allele was a
protective factor for CHB infection, especially in Mongoloid
populations. Our analysis was restricted in CHB and HC case,
thus our case size was smaller, but higher specificity would provide
us more reliable evidence to our conclusion. Taken together, -308
A may play a crucial role in anti-virus mechanism in human body;
it can not only protect healthy people from HBV infection but also
enhance the scavengingof virus while being infected. This virus
clearing function of TNF-,alpha. –308A allele was associated
with the enhancement of TNF-,alpha. transcriptional activation
as well as production [29,30].
Our study showed that -863 CC and -863 AA might be another
important factors in HBV clearance. Previous study reported that
the -863 C/A performed their protective or deteriorative function
for CHB infection through a difference way that -863 A allele can
lower TNF-,alpha. promoter activity and plasma levels by
weakening the affinity between specific protein and the segment of
TNF-,alpha. promoter spanning from position 2876 to position
2845 [31].
Although the association between TNF-,alpha. and HCC
patient has not been clearly understood, our studies gave some
indirect evidence on a different response to the TNF-,alpha. in
CHB and HCC individuals, for the discard of HCC cases from the
analysis could affect the results, especially in -863 CC vs. AA
Figure 1. Flow diagram of identifying potential studies in our meta-analysis.
doi:10.1371/journal.pone.0019606.g001
TNF-alpha Polymorphisms and HBV Infection Outcome
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19606T
a
b
l
e
1
.
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
S
t
u
d
i
e
s
I
n
c
l
u
d
e
d
i
n
t
h
e
M
e
t
a
-
a
n
a
l
y
s
i
s
.
S
t
u
d
i
e
s
(
Y
e
a
r
/
C
o
u
n
t
r
i
e
s
)
A
g
e
(
m
e
a
n
±
S
D
)
C
a
s
e
o
f
C
H
B
(
M
a
l
e
s
/
%
)
C
a
s
e
o
f
H
C
(
M
a
l
e
s
/
%
)
M
e
t
h
o
d
s
S
t
u
d
i
e
d
P
o
l
y
m
o
r
p
h
i
s
m
s
F
i
n
d
i
n
g
s
C
H
B
H
C
H
o
h
l
e
r
,
T
.
[
9
]
(
1
9
9
8
/
G
e
r
m
a
n
y
)
N
A
N
A
7
1
(
N
A
)
3
2
(
N
A
)
P
C
R
2
2
3
8
,
2
3
0
8
T
h
e
T
N
F
-
,
a
l
p
h
a
.
2
2
3
8
G
G
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
t
h
e
C
H
B
a
n
d
r
e
c
o
v
e
r
e
d
i
n
d
i
v
i
d
u
a
l
s
K
i
m
,
Y
.
J
.
[
7
]
(
2
0
0
3
/
K
o
r
e
a
)
M
a
l
e
4
9
.
9
6
1
0
.
4
;
F
e
m
a
l
e
5
0
.
8
6
1
0
.
6
M
a
l
e
5
4
.
7
6
1
0
.
9
;
F
e
m
a
l
e
5
3
.
6
6
1
1
.
0
1
1
0
9
(
7
4
.
4
)
2
9
1
(
6
5
.
5
)
S
i
n
g
l
e
b
a
s
e
p
r
i
m
e
r
e
x
t
e
n
s
i
o
n
a
s
s
a
y
2
1
6
3
,
2
2
3
8
,
2
3
0
8
,
2
8
5
7
,
2
8
6
3
,
1
0
3
1
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
A
A
o
r
G
A
o
r
-
8
6
3
C
/
C
w
e
r
e
s
t
r
o
n
g
l
y
a
s
s
o
c
i
a
t
e
d
w
i
t
h
t
h
e
r
e
s
o
l
u
t
i
o
n
o
f
H
B
V
i
n
f
e
c
t
i
o
n
Z
h
a
n
g
,
P
.
A
[
2
3
]
(
2
0
0
4
/
C
h
i
n
a
)
5
4
.
7
6
1
4
.
8
5
6
.
4
6
1
4
.
0
1
3
1
(
6
7
.
9
)
1
6
5
(
6
6
.
1
)
P
C
R
-
R
F
L
P
2
2
3
8
,
2
3
0
8
,
2
8
5
7
2
8
6
3
,
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
A
a
l
l
e
l
e
a
n
d
-
8
6
3
A
a
l
l
e
l
e
m
a
y
h
a
v
e
a
f
a
v
o
r
a
b
l
e
e
f
f
e
c
t
i
n
t
h
e
c
l
e
a
r
a
n
c
e
o
f
H
B
V
.
L
i
,
H
.
Q
.
[
1
7
]
(
2
0
0
6
/
C
h
i
n
a
)
3
3
.
3
7
6
1
2
.
6
7
3
4
.
6
8
6
1
1
.
3
4
4
3
3
(
8
1
.
8
)
2
4
4
(
5
5
.
8
)
P
C
R
2
2
3
8
,
2
8
5
7
T
h
e
f
r
e
q
u
e
n
c
y
o
f
-
2
3
8
G
G
g
e
n
o
t
y
p
e
i
n
s
e
l
f
-
l
i
m
i
t
e
d
g
r
o
u
p
w
a
s
s
i
g
n
i
f
i
c
a
n
t
l
y
h
i
g
h
e
r
t
h
a
n
c
h
r
o
n
i
c
H
B
V
g
r
o
u
p
.
T
h
e
f
r
e
q
u
e
n
c
y
o
f
T
N
F
-
,
a
l
p
h
a
.
-
8
5
7
C
C
i
n
c
h
r
o
n
i
c
H
B
g
r
o
u
p
w
a
s
s
i
g
n
i
f
i
c
a
n
t
l
y
h
i
g
h
e
r
t
h
a
n
s
e
l
f
-
l
i
m
i
t
e
d
g
r
o
u
p
N
i
r
o
,
G
.
A
.
[
8
]
(
2
0
0
5
/
I
t
a
l
y
)
5
2
6
1
2
4
6
.
3
6
7
.
4
1
8
4
(
8
1
.
5
)
9
6
(
7
9
.
2
)
D
N
A
s
e
q
u
e
n
c
i
n
g
2
2
3
8
,
2
3
0
8
,
2
8
6
3
,
2
1
0
3
1
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
G
G
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
a
n
u
n
f
a
v
o
r
a
b
l
e
p
r
o
g
n
o
s
i
s
i
n
p
a
t
i
e
n
t
s
w
i
t
h
c
h
r
o
n
i
c
H
B
V
i
n
f
e
c
t
i
o
n
.
C
h
e
o
n
g
,
J
.
Y
.
[
1
0
]
(
2
0
0
6
/
S
o
u
t
h
K
o
r
e
a
)
3
7
.
7
4
6
8
.
9
0
4
7
.
9
6
6
s
8
.
7
7
2
6
1
(
7
5
.
1
)
2
0
4
(
7
2
.
5
)
S
i
n
g
l
e
b
a
s
e
p
r
i
m
e
r
e
x
t
e
n
s
i
o
n
a
s
s
a
y
2
2
3
8
,
2
3
0
8
T
h
e
T
N
F
-
,
a
l
p
h
a
.
2
3
0
8
a
n
d
2
2
3
8
w
e
r
e
n
o
t
d
i
f
f
e
r
e
n
t
b
e
t
w
e
e
n
t
h
e
c
l
e
a
r
a
n
c
e
a
n
d
t
h
e
p
e
r
s
i
s
t
e
n
c
e
g
r
o
u
p
S
o
m
i
,
M
.
H
.
[
1
2
]
(
2
0
0
6
/
I
r
a
n
)
N
A
N
A
1
0
0
(
N
A
)
9
1
(
N
A
)
P
C
R
2
3
0
8
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
A
h
a
d
n
o
a
s
s
o
c
i
a
t
i
o
n
w
i
t
h
d
e
v
e
l
o
p
m
e
n
t
o
f
c
h
r
o
n
i
c
H
B
V
i
n
f
e
c
t
i
o
n
K
u
m
m
e
e
,
P
.
[
2
0
]
(
2
0
0
7
/
T
h
a
i
l
a
n
d
)
W
i
t
h
H
C
C
:
5
0
.
8
6
1
3
.
9
5
1
.
0
6
1
2
.
3
W
i
t
h
H
C
C
:
1
0
0
(
6
8
.
0
)
1
0
0
(
4
8
.
0
)
P
C
R
-
R
F
L
P
2
2
3
8
,
2
3
0
8
,
2
8
6
3
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
8
6
3
A
/
A
o
r
A
/
C
g
e
n
o
t
y
p
e
w
e
r
e
a
s
s
o
c
i
a
t
e
d
w
i
t
h
i
n
c
r
e
a
s
e
d
t
h
e
T
N
F
-
,
a
l
p
h
a
.
l
e
v
e
l
s
i
n
t
h
e
l
i
v
e
r
i
n
r
e
s
p
o
n
s
e
t
o
H
B
V
i
n
f
e
c
t
i
o
n
a
n
d
i
n
d
u
c
e
d
h
e
p
a
t
o
c
y
t
e
d
a
m
a
g
e
.
W
i
t
h
o
u
t
H
C
C
:
5
7
.
5
6
1
4
.
2
W
i
t
h
o
u
t
H
C
C
:
5
0
(
6
0
.
0
)
R
i
b
e
i
r
o
,
C
.
S
.
[
1
1
]
(
2
0
0
7
/
B
r
a
z
i
l
)
3
7
6
1
1
.
6
5
3
9
.
5
6
1
0
.
2
3
0
(
6
0
.
0
)
4
1
(
4
8
.
8
)
P
C
R
2
3
0
8
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
G
/
A
h
a
d
n
o
a
s
s
o
c
i
a
t
i
o
n
b
e
t
w
e
e
n
c
h
r
o
n
i
c
p
a
t
i
e
n
t
s
a
n
d
s
e
l
f
-
l
i
m
i
t
e
d
i
n
f
e
c
t
i
o
n
X
i
n
g
,
P
,
X
[
2
2
]
(
2
0
0
7
/
C
h
i
n
a
)
3
9
.
6
5
6
1
9
.
3
3
8
.
5
6
1
8
.
2
1
1
1
(
8
5
.
6
)
1
0
0
(
6
6
.
0
)
G
e
n
e
C
h
i
p
s
2
2
3
8
,
2
3
0
8
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
G
G
a
n
d
G
a
l
l
e
l
e
w
e
r
e
h
i
g
h
e
r
i
n
c
h
r
o
n
i
c
H
B
V
i
n
f
e
c
t
i
o
n
g
r
o
u
p
t
h
a
n
c
o
n
t
r
o
l
g
r
o
u
p
,
b
u
t
n
o
a
s
s
o
c
i
a
t
i
o
n
b
e
t
w
e
e
n
T
N
F
-
,
a
l
p
h
a
.
2
2
3
8
a
n
d
H
B
V
i
n
f
e
c
t
i
o
n
w
a
s
f
o
u
n
d
.
C
h
e
n
,
D
.
Q
.
[
6
]
(
2
0
1
0
/
C
h
i
n
a
)
4
0
.
9
6
1
0
.
9
N
A
2
5
2
(
6
0
.
7
)
1
0
9
(
5
5
.
0
)
P
C
R
-
R
F
L
P
2
2
3
8
,
2
3
0
8
,
2
8
5
7
,
2
8
6
3
T
h
e
T
N
F
-
,
a
l
p
h
a
.
-
3
0
8
G
/
G
g
e
n
o
t
y
p
e
w
a
s
m
o
r
e
f
r
e
q
u
e
n
t
i
n
p
a
t
i
e
n
t
s
t
h
a
n
c
o
n
t
r
o
l
s
,
w
h
i
l
e
t
h
e
f
r
e
q
u
e
n
c
i
e
s
o
f
T
N
F
-
3
0
8
A
/
G
g
e
n
o
t
y
p
e
w
a
s
h
i
g
h
e
r
i
n
c
o
n
t
r
o
l
s
t
h
a
n
i
n
t
h
e
p
a
t
i
e
n
t
g
r
o
u
p
W
a
n
,
P
.
Q
[
2
1
]
(
2
0
1
0
/
C
h
i
n
a
)
5
4
.
7
6
1
4
.
8
5
6
.
4
6
1
4
.
0
7
4
(
5
9
.
5
)
6
4
(
6
2
.
5
)
P
C
R
-
R
F
L
P
2
8
5
7
,
2
8
6
3
I
n
G
u
a
n
g
x
i
p
o
p
u
l
a
t
i
o
n
,
t
h
e
T
N
F
-
,
a
l
p
h
a
.
-
8
6
3
A
A
m
i
g
h
t
g
o
a
g
a
i
n
s
t
t
h
e
c
l
e
a
r
a
n
c
e
o
f
H
B
V
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
C
H
B
,
c
h
r
o
n
i
c
H
B
V
i
n
f
e
c
t
i
o
n
;
H
C
,
H
B
V
c
l
e
a
r
a
n
c
e
;
H
C
C
,
h
e
p
a
t
o
c
e
l
l
u
l
a
r
c
a
r
c
i
n
o
m
a
;
P
C
R
,
p
o
l
y
m
e
r
a
s
e
c
h
a
i
n
r
e
a
c
t
i
o
n
;
P
R
L
P
,
r
e
s
t
r
i
c
t
i
o
n
f
r
a
g
m
e
n
t
l
e
n
g
t
h
p
o
l
y
m
o
r
p
h
i
s
m
;
N
A
,
N
o
t
A
p
p
l
i
c
a
b
l
e
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
1
9
6
0
6
.
t
0
0
1
TNF-alpha Polymorphisms and HBV Infection Outcome
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19606model, thus, caution should be paid in this result and more
investigations are demanded to interpret the relationship among
TNF-,alpha. and HCC and CHB.
In addition, we found that genotype GG at position -238 of
TNF-a promoter was associated with decreased risk of chronic
HBV persistence in European populations which supports the
study of Hohler et al [9]. However, the results differed from the
study of Lu et al [32]. The current results suggest that ethnicity
may have played an important role in HBV infection outcome,
leading to results inconsistent with that of others. Further
Table 2. Meta-analysis of effect of TNF-a promoter polymorphisms on the risk of HBV persistence.
Genotype comparisons
NO. of
CHB
NO. of
HC OR [95% CI,] Z (p value) Heterogeneity of study design
x
2 df (P –value) I
2
21031 T allele vs. C allele Overall 1617 495 0.86[0.68,1.08] 1.27(0.21) 0.01 1(0.90) 0%
TT vs. CC Overall 827 263 0.54[0.29,1.02] 1.89(0.06) 0.21 1(0.65) 0%
TT vs. TC +CC Overall 1222 379 0.82[0.65,1.05] 1.55(0.12) 0.06 1(0.81) 0%
CC vs. TC +TT Overall 1222 379 1.77[0.94,3.31] 1.78(0.08) 0.26 1(0.61) 0%
2863 C allele vs. A allele Overall 2450 1387 0.91[0.78,1.07] 1.11(0.27) 8.40 5(0.14) 40%
Asian 2208 1262 0.91 [0.77,1.08] 1.06 (0.29) 8.40 4(0.08) 52%
CC vs. AA Overall 1312 743 0.64[0.42,0.97] 2.09 (0.04) 5.11 5(0.40) 2%
Asian 1107 676 0.64[0.42,0.99] 2.01 (0.04) 5.10 4(0.28) 22%
CC vs. CA+AA Overall 1881 1065 0.95[0.68,1.33] 0.29 (0.77) 17.06 5(0.004) 71%
Asian 1697 969 0.97[0.65,1.44] 0.16(0.87) 17.06 4(0.002) 77%
AA vs. CA+CC Overall 1866 1065 1.60 [1.06,2.41] 2.25(0.02) 6.21 5(0.29) 19%
Asian 1682 969 1.60[1.05,2.45] 2.18(0.03) 6.21 4(0.18) 36%
2857 C allele vs. T allele Asian 1993 851 1.04[0.85,1.28] 0.38(0.70) 5.55 2(0.06) 64%
CC vs. TT Asian 1215 527 0.90[0.51,1.59] 0.35(0.73) 2.20 2(0.33) 9%
CC vs. CT +TT Asian 1604 689 1.13[0.69,1.85] 0.47(0.64) 9.47 2(0.009) 79%
TT vs.C T +CC Asian 1604 689 1.15[0.65,2.01] 0.47(0.64) 2.08 2(0.35) 4%
2308 G allele vs. A allele Overall 2175 1171 1.30[1.04,1.63] 2.30(0.02) 7.50 7(0.38) 7%
Asian 1832 964 1.41[1.08,1.83] 2.56(0.01) 4.89 4(0.30) 18%
European 304 159 1.15[0.70,1.89] 0.56(0.57) 0.58 1(0.45) 0%
GG vs. AA Overall 2012 1178 0.62[0.23,1.67] 0.94(0.35) 0.98 6(0.98) 0%
Asian 1785 1047 0.67[0.19,2.33] 0.64(0.52) 0.44 3(0.93) 0%
European 206 97 0.35[0.04,2.95] 0.97(0.33) 0.02 1(0.89) 0%
GG vs. GA+AA Overall 1967 1012 1.35[1.08,1.70] 2.59(0.01) 9.20 7(0.24) 24%
Asian 1682 843 1.47[1.13,1.91] 2.85(0.004) 5.58 4(0.23) 28%
European 384 258 1.31[0.90,1.91] 1.41(0.16) 0.54 2(0.76) 0%
AA vs. GA +GG Overall 2271 1373 1.57[0.59,4.17] 0.90(0.37) 1.33 6(0.97)* 0%
Asian 1836 1113 1.65[0.40,6.77] 0.69(0.49) 0.24 2(0.89) 0%
European 384 258 1.49[0.47,4.71] 0.68(0.50) 0.26 2(0.88) 0%
2238 G allele vs. A allele Overall 2715 1588 0.92[0.72,1.18] 0.65(0.52) 12.25 8(0.14) 35%
Asian 2421 1451 1.01 [0.77,1.33] 0.10(0.92) 8.36 6(0.21) 28%
European 294 137 0.50 [0.77,1.33] 1.87(0.06) 1.22 1(0.27) 18%
GG vs. AA Overall 2281 1384 0.88[0.32,2.45] 0.52(0.70) 0.52 4(0.97) * 0%
Asian 2065 1265 0.83 [0.25,2.70] 0.23(0.75) 0.23 2(0.89) 0%
European 216 119 1.07 [0.14,8.28] 0.24(0.95) 0.24 1(0.62) 0%
GG vs. GA+AA Overall 2498 1486 0.90[0.70,1.16] 0.42(0.42) 14.68 8(0.07) 46%
Asian 2243 1358 1.01[0.77,1. 32] 0.07(0.95) 9.52 6(0.15) 37%
European 255 128 0.45[0.22,0.93] 2.15(0.03) 1.77 1(0.18) 44%
AA vs.G A+GG Overall 2498 1486 1.08[0.39,2.98] 0.14(0.89) 0.66 4(0.96) 0%
Asian 2243 1358 1.18[0.36,3.86] 0.27(0.79) 0.20 2(0.90) 0%
European 255 128 0.81[0.11,6.16] 0.20(0.84) 0.34 1(0.56) 0
*-308 A/A and -238 A/A were rare genotypes. Therefore, some studies had to be excluded because they contained no individuals carrying these genotypes. In the study
on -308 AA vs.G A+GG, the report by Kummee et al [20] was excluded; in -238 GG vs. AA and -238 AA vs.G A+GG, Cheong et al [10] and Li et al [17] were excluded.
Abbreviations: CHB, chronic HBV infection; HC, HBV clearance; OR, odds ratio; CI, confidence interval; df, degree of freedom.
doi:10.1371/journal.pone.0019606.t002
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19606Figure 2. OR of HBV infection associated with TNF-,alpha.-863 C/A for the CC genotype compared with the AA genotypes and AA
compared to the CA+AA genotype.
doi:10.1371/journal.pone.0019606.g002
Figure 3. OR of HBV infection associated with TNF-,alpha.-308 G/A for the G allele compared with the A allele and the GG
genotype compared with the GA+AA genotypes.
doi:10.1371/journal.pone.0019606.g003
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19606research is needed to demonstrate the underlying cause for this
inconsistency.
In our study, other polymorphisms in the TNF-,alpha.
promoter (-1031T/C,-857C/T) did not show any association with
HBV outcome, which is different from some previous reports
[7,9,17]. Possible explanations for this difference are a lack of data,
and ethnicity diversity.
Our study provided a more believable result due to a larger size
sample, and provides explanations for the inconsistencies observed
in previous studies. Meta-analysis is a powerful statistical tool that
provides a consensus by combining the data from diverse studies
that reveal inconsistent results on the same problem. Some results
of our study did not show any statistical significance although we
combined relatively large numbers of studies. However, subgroup
analysis by ethnicity showed a statistical significant result. Hence, a
meaningful outcome can be produce only when it is correctly used.
On the other hand, the more studies included, the more accurate
the results would be.
In conclusion, this study provides evidence of a positive
association between HBV clearance and TNF-,alpha. promoter
-863 CC. Conversely, -308 GG/GG+GA genotypes increased the
risk of chronic infection. These genotypes might affect the
outcome of HBV infection through regulation of TNF-,alpha.
transcriptional activation and production. Ethnic diversity may
complicate the outcome of infection. More studies of individuals of
diverse ethnicities will be necessary to determine the effects of
TNF-,alpha. promoter polymorphisms on the outcome of HBV
infection.
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